Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Kidney and Dialysis
Special Issues
COVID-19 and the Kidney
share announcement

COVID-19 and the Kidney

A special issue of Kidney and Dialysis (ISSN 2673-8236).

Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 3785

Special Issue Editors

Dr. Giuliano Brunori

E-Mail Website
Guest Editor
Division of Nephrology and Dialysis, Ospedale Santa Chiara, Trento, Italy
Interests: nephrology; chronic kidney disease; dialysis
Dr. Massimo Torreggiani

E-Mail Website
Guest Editor
Néphrologie Et Dialyse, Centre Hospitalier Le Mans, 194 Avenue Rubillard, 72000 Le Mans, France
Interests: chronic kidney disease; nutrition in CKD; diabetic nephropathy; aging; dialysis; pregnancy and CKD
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

SARS-CoV-2 has been ravaging the world for almost two years now. The epidemic has had a profound impact on the general population, but our chronic kidney disease, dialysis and kidney transplant patients have been facing an even greater share of the risk. The pandemic has posed new challenges to nephrologists: from virus-associated electrolyte disorders in intensive care units (ICUs) to the management of older patients with COVID-19 end-stage renal disease, refused by ICUs, in dialysis wards; new COVID-19-related kidney diseases have been discovered, and transplant programs have experienced an unprecedented slowdown. Furthermore, COVID-19-related acute kidney injury has been observed in up to 45% of ICU patients, with specific features and pathogenic mechanisms, contributing to the high mortality of the infection.

Moreover, the availability of vaccines has revealed the low response rate of immunodepressed patients and the lability of the immune response in the general population as well as in dialysis and transplant patients; as a result, the best vaccination schedule is still a matter of debate. Finally, the long-term renal consequences of SARS-CoV-2 infection are still unknown.

Protecting and taking care of our fragile patients has been our priority. During these busy months, our clinical and research work has never stopped; however, most of us did not have enough time to share our experiences and observations with the scientific community.

Kidney and Dialysis is a new and dynamic journal which aims to become a reference in the nephrology field. We would like to encourage you to share your experience concerning all aspects of the COVID-19 pandemic in CKD, dialysis and kidney transplant patients, and to submit your data to this Special Issue.

Dr. Giuliano Brunori
Dr. Massimo Torreggiani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Kidney and Dialysis is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SARS-CoV-2
  • chronic kidney disease
  • dialysis
  • kidney transplant
  • intensive care units
  • ICUs
  • COVID-19
  • vaccines
  • renal consequences
  • nephrology

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1290 KiB  
Article
SARS-CoV-2 mRNA Vaccine Immunogenicity in Hemodialysis Patients: Promising Vaccine Protection That May Be Hindered by Fluid Overload
by Hedia Hebibi, Marvin Edeas, Laure Cornillac, Severine Beaudreuil, Jedjiga Achiche, David Attaf, Samah Saibi, Charles Chazot, Fatah Ouaaz and Bernard Canaud
Kidney Dial. 2022, 2(1), 44-56; https://doi.org/10.3390/kidneydial2010006 - 28 Jan 2022
Cited by 2 | Viewed by 3139
Abstract
Background: Due to their immunocompromised conditions, hemodialysis (HD) patients are at high risk of being infected with SARS-CoV-2 with poor clinical outcomes. We explored safety, efficacy and variability factors associated with vaccine immune response in these patients. Methods: From 18 January [...] Read more.
Background: Due to their immunocompromised conditions, hemodialysis (HD) patients are at high risk of being infected with SARS-CoV-2 with poor clinical outcomes. We explored safety, efficacy and variability factors associated with vaccine immune response in these patients. Methods: From 18 January to 30 April 2021, 87 HD patients were enrolled in this study and subdivided in two sub-groups: SARS-CoV-2 positive prior to vaccination and naïve patients. The vaccination protocol included two intramuscular shots of the mRNA vaccine at a 28-day interval. The vaccine response was evaluated one month after the first and second shots by measuring anti-S antibody titers. Findings: 44% of the patients studied, were women; median age was 58 years. One month after the first shot, 64.3% of patients had anti-S antibody titers < 50 U/mL while 96.5% had anti-S antibody titers > 250 U/mL one month after the second shot. We show that the anti-SARS-CoV-2 spike mRNA vaccine elicits a great tolerability in HD patients. Importantlly, the vaccine response is characterized by a higher rate of seroconversion than conventional vaccination, as we have shown for the hepatitis B vaccine. We highlight two major factors of variability of the vaccine response. First, pre-exposure to SARS-CoV-2 boosts humoral response, as 95% of SARS-CoV-2 positive patients developed anti-S antibody titers > 250 U/L just after the first shot. Secondly, on the contrary fluid overload strikingly appears, limiting the vaccine response, as 84% of HD patients with fluid overload elicit lower anti-S antibody titers after the first shot. Interpretation: Our findings show that the immunogenic profile induced by mRNA vaccines in HD patients represents a promising a protective strategy that is associated with greater tolerability. Fluid overload may be considered as a novel factor that hinders the immune response in HD patients and further studies will be needed to investigate this working hypothesis. Full article
(This article belongs to the Special Issue COVID-19 and the Kidney)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop